Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ascletis Pharma, Inc. ( (HK:1672) ) has issued an announcement.
Ascletis Pharma Inc. has announced its 2025 Annual General Meeting, scheduled for May 22, 2025, in Hangzhou, China. The meeting will address several key business items, including the consideration of the company’s audited financial statements for 2024, the re-election of directors, and the re-appointment of KPMG as the auditor. Additionally, resolutions will be proposed to authorize the company’s board to manage share allotments and repurchases, potentially impacting the company’s capital structure and shareholder value.
More about Ascletis Pharma, Inc.
Ascletis Pharma Inc. is a biopharmaceutical company incorporated in the Cayman Islands, focusing on developing innovative drugs for the treatment of liver diseases, viral infections, and cancer. The company is listed on the Hong Kong Stock Exchange.
YTD Price Performance: 108.64%
Average Trading Volume: 7,620,590
Technical Sentiment Signal: Sell
Current Market Cap: HK$6.09B
For an in-depth examination of 1672 stock, go to TipRanks’ Stock Analysis page.